Navigation Links
RNA build-up linked to dementia and motor neuron disease
Date:10/30/2013

A new toxic entity associated with genetically inherited forms of dementia and motor neuron disease has been identified by scientists at the UCL Institute of Neurology. The toxin is the result of a genetic mutation that leads to the production of RNA molecules which could be responsible for the diseases. The findings are published in the journal Acta Neuropathologica.

Frontotemporal dementia and motor neuron disease are related neurodegenerative diseases that affect approximately 15,000 people in the UK. Frontotemporal dementia causes profound personality and behaviour changes. Motor neuron disease leads to muscle weakness and eventual paralysis.

The most common known cause for both frontotemporal dementia and motor neuron disease is an unusual genetic mutation in the C9orf72 gene. The mutation involves a small string of DNA letters at the beginning of the gene, which expand massively to produce thousands of copies.

The new research, funded by Alzheimer's Research UK and the Medical Research Council, has shown that this DNA expansion acts in a peculiar way, leading to the generation of unexpected RNA molecules that could cause the disease.

When a gene is turned on, an RNA copy of the gene's DNA is generated. The gene's DNA code has directionality, so that it is normally turned on in only one direction, termed the 'sense direction'. The new research shows that the DNA expansion is turned on in both directions.

This leads to the normal sense RNA being produced, as well as RNA in the opposite direction, termed 'antisense RNA'. Both RNA types accumulate into aggregates in the neurons of people with frontotemporal dementia.

Intriguingly, the research showed that people with more of these aggregates in their brains developed the disease earlier than people with less RNA aggregates. This correlation suggests that the build-up may be important in causing frontotemporal dementia and motor neuron disease, making the C9orf72 DNA expansion a potential target for therapy.

Dr Adrian Isaacs, lead researcher at the UCL Institute of Neurology, said: ""These findings identify new, potentially toxic molecules in diseases caused by DNA expansions. The next steps will be to determine how they might kill neurons and how to stop them building up."

Dr Simon Ridley, Head of Research at Alzheimer's Research UK, the UK's leading dementia research charity, said: "The discovery of the C9ORF72 gene was a major step forward for research into frontotemporal dementia and motor neuron disease, and it's positive to see researchers beginning to untangle how this gene may cause these diseases in some people.

"Alzheimer's Research UK is delighted to have supported this promising study. By unravelling some of the biological mechanisms at play, this research could take us further on the road to new treatments that are so desperately needed by the thousands of people with these devastating diseases. For these results to reach their full potential it's vital that we continue to invest in research."


'/>"/>

Contact: David Weston
d.weston@ucl.ac.uk
44-203-108-3844
University College London
Source:Eurekalert

Related medicine news :

1. Cancer drug prevents build-up of toxic brain protein
2. Protein build-up leads to neurons misfiring
3. Weight at time of diagnosis linked to prostate cancer mortality
4. Male birth defect is weakly linked to pesticide exposure, Stanford-led study finds
5. Poor motor performance linked to poor academic skills in the first school years
6. Early skin-to-skin contact linked to higher breastfeeding rates
7. Headaches in lupus patients not linked to disease activity study says
8. Prevalence of household gun ownership linked to child gun shot wounds
9. Casey Gollan: A Step-by-Step Guide to Creating a LinkedIn Account
10. High blood sugar levels linked to increased wound complications after surgery
11. Abuse, lack of parental warmth in childhood linked to multiple health risks in adulthood
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , ... February 05, 2016 , ... ... setting the stage for new clinical and scientific initiatives have all marked the ... she was appointed President and CEO of the nation’s oldest cancer center, Candace ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... College President George H. Van Allen have signed a joint enrollment and degree ... a seamless pathway toward associate and baccalaureate degrees at FHU|Dickson. , The ...
(Date:2/5/2016)... ... 05, 2016 , ... The American public tends to feel uncomfortable about drinking ... regular municipal or well water. The recent experience with lead contaminated water in Flint, ... long way toward increasing public acceptance of recycled waste water as drinking water. ...
(Date:2/5/2016)... ... 05, 2016 , ... At its annual meeting held last week, the American ... National Board of Directors. Mr. McDermott succeeds former APDA Chairman, Fred Greene. , "We ... Chambers , APDA President and CEO. “Pat has tirelessly served APDA since 2001 when ...
(Date:2/5/2016)... ... February 05, 2016 , ... In sleep, when the defenses of the day ... feature of patients with eating disorders is significant self-criticism, and consequently these patients experience ... are regarded as maladaptive means for coping with this unease, but also leads to ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... CENTENNIAL, Colo. , Feb. 5, 2016  As ... about health. The multitude of recommended screenings and tests ... healthy aging a priority. However, for the majority of ... of proactive health planning. For the 37.5 million American ... time like the present to make hearing health a ...
(Date:2/5/2016)... 2016 Aethlon Medical, Inc. (Nasdaq: AEMD ), ... will be presenting at Source Capital Group,s 2016 Disruptive Growth ... at 2:15 p.m. ET on Wednesday, February 10, 2016.  ... taking place at 3:15 p.m. ET. http://www.aethlonmedical.com .  ... after the conclusion of the live event. The panel discussion ...
(Date:2/5/2016)... 2016  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... underwritten secondary offering of 11,027,558 shares of its common ... of Blackstone and Goldman Sachs.  The shares are being ... $96.45 per share. The selling stockholders will receive all ... nor any of its directors, officers or other stockholders ...
Breaking Medicine Technology: